This protocol addresses patients with an advanced solid tumour — including lung cancer, renal cancer, and other solid tumour primaries outside of breast and prostate — who have clinically significant bone metastases and a life expectancy of at least 3 months.
Management centres on a bone-modifying agent administered at regular intervals. For eligible patients, the treatment schedule may be de-escalated after an initial phase of therapy. The complete selection criteria, agent options, interval guidance, and monitoring parameters are set out in the structured protocol.
DOI: 10.1016/j.annonc.2020.07.019
Zoledronate or denosumab is recommended in patients with advanced lung cancer, renal cancer and other solid tumours with a life expectancy of 3 months and clinically significant bone metastases.
Most patients selected for treatment with zoledronate can de-escalate this agent safely to administration every 12 weeks, preferably after monthly treatment for 3–6 months.
Denosumab should be administered every 4 weeks.
View source ↗